17-November-2026
Corporate News
 
Biocon gets US FDA approval for cancer biosimilar Pebrilzo; launch expected in 2028
16-Nov-2026

Biocon has received approval from the US Food and Drug Administration for Pebrilzo (pertuzumab-qcay), a biosimilar of Roche’s Perjeta (pertuzumab), used to treat HER2-positive breast cancer. The approval strengthens Biocon’s oncology portfolio in the US, taking its total number of approved cancer biosimilars in the country to five. Pebrilzo is a monoclonal antibody that works by blocking HER2 receptors on cancer cells. The treatment is intended for patients with HER2-positive breast cancer.

News Source:- https://www.financialexpress.com/business/industry-biocon-gets-us-fda-approval-for-cancer-biosimilar-pebrilzo-launch-expected-in-2028-4385578/?ref=morelatest_hp